Clinical distribution of yeast infection in aseptic parts of patients with liver disease and sensitivity analysis of antifungal drugs

Abstract

Abstract:

Objective Invasive yeast infection is closely related to the infection rate of patients with low immunity such as intensive care unit and organ transplantation. This study analyzed the clinical distribution characteristics of yeast infection in the sterile site, and analyzed the in vitro antifungal activity of seven drugs. Methods The minimum inhibitory concentration (MIC) of 188 yeast strains collected from the 302th hospital of PLA from 2012 to 2017 was determined. The clinical distribution characteristics of 188 yeasts were analyzed. Results Candida albicans (45.7%) is the main yeast causing infection in the aseptic site of patients with liver disease, followed by Candida tropicalis (18.1%) and Candida glabrata (16.0%), and the infected site is mainly ascites fluid (39.9%); Mainly between 50 and 65 years old (43.6%), and mainly patients were male (70.7%). Candida glabrata is the mainly non-Candida albican that causes infection in the age of 50-65 years; drug sensitivity test demonstrated that the MIC₅₀ of itraconazole against Candida albicans was 0.25 μ g/mL and MIC₉₀ was 0.5 μ g/mL, while the MIC₅₀ of caspofungin to Candida krusei was 0.25 μ g/mL while MIC₉₀ reached at 0.5 μ g/mL except for Candida albicans on itraconazole the sensitivity is low (19.8%) and the sensitivity of Candida krusei to the caspofungin is low (33.3%), triazole drugs, echinocanins and 5-fluorocytosine have high in vitro antifungal activity against yeast. Conclusion Candida albicans was still the main strain of invasive yeast infection. The infected patients are mainly male. The antifungal drugs have different antifungal activities against Candida albicans and non-Candida albicans. The antifungal drugs should be selected reasonably.

Key words: sterile site, yeast, distribution characteristics, in vitro antifungal activity

CLC Number:

R519.3

ZHANG Jing-xia, CUI En-bo, ZHANG Ju-ling, GUO Li-na, XU Ying-chun, QU Fen. Clinical distribution of yeast infection in aseptic parts of patients with liver disease and sensitivity analysis of antifungal drugs[J]. Chinese Journal of Mycology, 2020, 15(1): 15-21.

References

[1] Guinea J. Global trends in the distribution of Candida species causing candidemia[J]. Clin Microbiol Infect,2014, 20(Suppl 6):5-10.
[2] Wu PF, Liu WL, Hsieh MH,et al. Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients[J]. Emerg Microbes Infect,2017, 6(10):e87.
[3] Lortholary O, Renaudat C, Sitbon K,et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)[J]. Intensive Care Med,2014, 40(9):1303-1312.
[4] Pfaller MA, Andes DR, Diekema DJ,et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients:data from the prospective antifungal therapy (PATH) registry 2004-2008[J]. PLoS One,2014,9:e101510.
[5] Papon N, Courdavault V, Clastre M,et al Emerging and emerged pathogenic Candida species:beyond the Candida albicans paradigm[J]. PLoS Pathog,2013, 9:e1003550.
[6] Sasso M, Roger C, Sasso M,et al. Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit:A 10-year study[J]. Mycoses,2017, 60:770-780.
[7] Lin CC,Liu CP, Hsieh FC,et al. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan[J]. Microbiol Immunol Infect,2015, 48:552-558.
[8] Berdal JE, Haagensen R, Ranheim T,et al. Nosocomial candidemia; risk factors and prognosis revisited; 11 years' experience from a Norwegian secondary hospital[J]. PLoS ONE 2014, 9:e103916.
[9] Wu Z, Liu Y, Feng X,et al. Candidemia:incidence rates, type of species, and risk factors at a tertiary care academic hospital in China[J]. Infect Dis,2014, 22:4-8.
[10] Yapar N. Epidemiology and risk factors for invasive candidiasis[J]. Ther Clin Risk Manag,2014,10:95-105.
[11] Guo LN, Xiao M, Cao B,et al. Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections across urban Beijing, China[J]. 2017, 12:1075-1086.
[12] Quindo's G. Epidemiology of candidaemia and invasive candidiasis. A changing face[J]. Rev Iberoam Micol,2014, 31:42-48.
[13] MaraRD, JackF. High-through put detection of pathogenic yeasts of the genus Trichosporon[J]. Clin Microbiol,2004,42(8):3696-3706.
[14] Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts:Third Edition:Approved standard CLSI M27-A3[S]. 2008, CLSI, PA, USA.
[15] Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010-2012[J]. Clin. Microbiol,2012, 50(9):2846-2856.
[16] Espinel-Ingroff A, Aller AI, Canton E,et al. Cryptococcus neoformans-Cryptococcus gattii species complex:an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole[J]. Antimicrob Agents Chemother,2012,56(11):5898-5906.
[17] Nanchal RS,Ahmad S.Infections in liver disease[J]. Critical Care Clinics,2016,32(3):411-424.
[18] Srivastava A, Malik R, Bolia R,et al. Prevalence, clinical profile and outcome of ascitic fluid infection in children with liver disease[J]. Pediatr Gastroenterol Nutr, 2017,64:194-199.
[19] Natarajan SK, Mukhopadhya A, Ramachandran A,et al. Spontaneous bacterial peritonitis results in oxidative and nitrosative stress in ascitic fluid[J]. Gastroenterol Hepatol,2007,22:177-181.
[20] Song KH, Jeon JH, Park WB,et al. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. A retrospective matched case-control study[J]. BMC Infect Dis,2009,9:41.
[21] Alexopoulou A, Vasilieva L, Agiasotelli D,et al. Fungal infections in patients with cirrhosis[J]. Hepatol,2015, 63:1043-1045.
[22] Bucsics T, Schwabl P, Mandorfer M,et al. Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP)[J]. Hepatol,2016, 64:1452-1454.
[23] Lamoth F, Lockhart SR, Berkow EL,et al. Changes in the epidemiological landscape of invasive candidiasis[J]. Antimichrob Chemother,2018, 73(suppl 1):i4-i13.
[24] Lotfi N,Shokohi T,Nouranibaladezaei SZ,et al. High recovery rate of non-albicans Candida species isolated from burn patients with candidemia in Iran. Jundishapur[J]. Microbiol,2015,8:e22929.
[25] Gupta A,Varma A. Candida glabrata candidemia:An emerging threat in critically ill patients. Indian[J]. Crit Care Med,2015, 19:151-154.
[26] Almirante B, Rodríguez D, Cuenca-Estrella M,et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections:case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003[J]. Clin Microbiol,2006, 44:1681-1685.
[27] Grossi PA, Gasperina DD, Barchiesi F,et al. Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients[J]. Transplant Proc,2011, 43:2463-2471.
[28] Cornely OA, Bassetti M, Calandra T,et al. guideline for the diagnosis and management of Candida diseases 2012:non-neutropenic adult patients[J]. Clin Microbiol Infect,2012,18(Suppl 7):19-37.
[29] Yeoh SF, Lee TJ, Chew KL,et al. Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation[J]. Infect Drug Resist,2018, 11:805-819.
[31] Arendrup MC, Perlin DS, Jensen RH,et al. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations[J]. Antimicrob Agents Chemother, 2012,56(5):2435-2442.
[32] Espinel-Ingroff A, Arendrup MC, Pfaller MA,et al. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods:should the clinical laboratory be testing this agent[J]? Antimicrob Agents Chemother, 2013,57(12):5836-5842.